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Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare
soft-tissue neoplasm that is locally aggressive but does not
metastasize. There is no standard systemic treatment for
symptomatic patients, although a number of agents are
used. Tyrosine kinase inhibitors have recently been reported
to show useful activity. We reviewed our bi-institutional
(Royal Marsden Hospital, Cambridge University Hospitals)
experience with the tyrosine kinase inhibitor pazopanib in
the treatment of progressing DT/AF. Eight patients with DT/
AF were treated with pazopanib at Royal Marsden Hospital
and Cambridge University Hospitals between June 2012
and June 2016. The median age of the patients was 37.5
(range: 27–60) years. The median duration of pazopanib
treatment was 12 (range: 5–22) months and for three
patients the treatment is ongoing. Three patients
discontinued treatment early (patient preference, intolerable
toxicity and logistical reasons, respectively). None of the
patients showed radiological progression while on
treatment, best responses according to Response
Evaluation Criteria In Solid Tumors 1.1 were partial
response in 3/8 and stable disease in 5/8 cases. Six
patients derived clinical benefit from treatment in terms of
improved function and/or pain reduction. Median
progression-free survival was 13.5 (5–36) months. Only one
patient experienced intolerable toxicity (grade 3
hypertension) leading to early treatment discontinuation. In
our series of patients with DT/AF, pazopanib demonstrated
important activity both in terms of symptom control (75%)
and absence of radiological progression (100%). Results of
ongoing confirmatory trials are eagerly awaited. Anti-
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Introduction
Desmoid tumour/aggressive fibromatosis (DT/AF) is a
rare neoplasm comprising ∼ 3% of all soft-tissue tumours.
These low-grade monoclonal proliferations fall within a
broad histologic spectrum of fibrous mesenchymal
tumours that range from benign proliferations of scar
tissue to high-grade fibrosarcomas [1]. DT/AF are unu-
sual in being both highly locally invasive and lacking
metastatic potential. Although the clinical course of DTs
rarely leads to a fatal outcome, these tumours have a
marked propensity to local recurrence and aggressive
expansion that can result in significant morbidity and
psychological distress [2].
The pathogenesis of DT/AF is complex and several
intracellular signalling pathways have been implicated.
Higher prevalence in females, during and after pregnancy,
systematic reports of spontaneous regression during
menopause support the role of oestrogens in the genesis
and maintenance of this disease [3]. Moreover, although
sporadic AF does not express oestrogen receptor α, they
display a nearly uniform expression of oestrogen receptor β
[4]. CTNNB1 mutations are described in nearly 85% of
cases of sporadic DF/AF, indicating the importance of the
Wnt/β-catenin pathway [5]. Indeed, nuclear expression of
β-catenin is used as a standard diagnostic test for this
disease. Transforming growth factor-β is an important
promoter of tissue growth and plays a key role in
angiogenesis and in fibroblastic proliferations like DT/AF
[6,7]. In a minority of cases the disease occurs in patients
with a germ-line mutation in APC, the gene for classic
familial adenomatous polyposis, or Gardner syndrome. DT/
AF in Gardner syndrome is more likely to have a truncal
site of origin, may develop after surgery and has a worse
prognosis than the sporadic type. It is particularly difficult
to treat when localized intra-abdominally [8].
Surgery, where technically feasible had until recently
been the mainstay of clinical management despite high
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rates of recurrence and significant post-treatment mor-
bidity [9,10]. However, a number of investigators repor-
ted the tendency for the disease to undergo spontaneous
stabilization and regression resulting in a revised treat-
ment algorithm such that asymptomatic patients have an
initial period of surveillance prior to a decision regarding
surgery or systemic treatment [11]. This is now the cur-
rent standard of care in most European centres [12,13].
In symptomatic patients or in those where tumour growth
threatens to compromise mobility or vital structures
several nonsurgical medical options may be proposed.
Pain is the most frequently mentioned, but often
underestimated symptom [13]. First-line systemic ther-
apy is commonly an antioestrogenic agent (i.e. tamoxifen,
toremifene) given with or without a NSAID such as
celecoxib, sulindac or naproxen [13,14]. The limited
toxicity, rare adverse events and low costs of NSAID/
antioestrogen treatment are in contrast with the delayed,
low response rates seen with this approach [13]. Upon
failure of hormonal manipulation or as an alternative first-
line option, chemotherapy can also be considered for
highly symptomatic patients. Several chemotherapeutic
agents, including anthracycline (doxorubicin or pegylated
lipoposomal doxorubicin) or methotrexate/vinca-alkaloid
based combinations have been explored with variable
success [15,16].
The choice and sequence of systemic treatment is not
based on any solid evidence due to a paucity of rando-
mized trials in DT/AF and is often driven by the
empirical experience of the treating clinician/institution
[12,13]. Radiotherapy is also a viable management
option, but there are concerns surrounding late effects
including the development of second malignancies which
is an important consideration, especially given the young
age of onset in most patients [12,13].
In part due to concerns of using cytotoxic drugs in young
patients alternative nonchemotherapeutic systemic treat-
ment options have recently been explored. Imatinib was
one of the first TKIs showing some initially very pro-
mising clinical activity in patients with progressive DF
[17]. However, in two more recent prospective, uncon-
trolled phase II studies [18,19] despite the relatively high
stabilization rates of around 60–80%, rather low objective
response rates (3 and 9%, respectively) were observed.
The use of the multitargeted TKI sorafenib resulted in
clinical benefit in two-thirds of patients in a retrospective
series, with somehow more substantial partial response
(PR) and stable disease rates of 25 and 70%, respectively
[20]. Importantly, 92% of patients showed features of
increased tumour fibrosis and loss of cellularity as
demonstrated by a quantifiable early change in MRI T2
signal. In a more recent update [21] on long-term results
of 79 patients the objective response rates were slightly
lower (17.7%) than the initial report, with a rather
impressive median progression-free survival (PFS) of
48.2 months.
Pazopanib is a multitargeted TKI of vascular endothelial
growth factor receptors 1, 2 and 3, platelet-derived
growth factor receptors α and β and KIT and is the first
such agent to show statistically significant PFS benefit in
a phase III trial of pretreated soft-tissue sarcomas [22].
We recently reported our initial pilot results with pazo-
panib in two patients with DT [23]. These data sup-
ported further investigation into the role of pazopanib in
DT/AF.
Patients and methods
We retrospectively analysed the medical records of eight
histologically confirmed DT/AF patients who received
pazopanib at the Royal Marsden Hospital (six patients)
and at Cambridge University Hospitals (two patients)
between June 2012 and June 2016. Data were gathered
on patient and disease characteristics including symp-
toms, number and type of prior surgeries, radiation
therapy, lines, duration and response to prior systemic
therapies (hormonal/NSAID, chemotherapy), dose and
toxicities of pazopanib, reason for treatment dis-
continuation and response to treatment. Radiological
assessments were made according to Response
Evaluation Criteria In Solid Tumors (RECIST), v1.1. by
a consultant radiologist (C.M.) from the Royal Marsden
Hospital with expertise in soft-tissue sarcomas. In addi-
tion, subjective assessments for changes in signal on
T2-weighted MRI were recorded. All patients consented
Table 1 Patient and prepazopanib treatment characteristics
Patient
number
Age (male/
female) Site
NSAID+ tamoxifen best response and PFS
(months)
Anthracycline best response and PFS
(months) Surgery RT
1 36 (female) Upper arm N+T; SD (6) D×4; SD (10) Tenolysis No
2 40 (female) Abdominal wall Intermittent use C+T (NA) LD×6; PR (60) None No
3 60 (female) Forearm C+T; SD (16) D×1-drug reaction; NA Two resections Yes
4 31 (female) Abdominal wall N+ T; PD (4) LD×6; SD (15) None No
5 39 (male) Upper arm N+T; PD (3) None prior to pazopanib None No
6 27 (male) Neck N+T; SD (7) LD×6; PR (19) Resection No
7 44 (female) Chest wall N+ T; SD (10) LD×11; SD (12) None No
8 17 (female) Chest wall/axilla None LD×3; SD (3) None No
C, celecoxib; D, doxorubicin; LD, liposomal doxorubicin; N, naproxen; NA, not available; PD, progressive disease; PFS, progression-free survival; PR, partial remission; RT,
radiotherapy; SD, stable disease; T, tamoxifen.
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for their clinical data to be processed and published for
scientific purposes.
Results
We treated six females and two males with DT/AF with
pazopanib. Median age at the initiation of pazopanib was
37.5 (range: 27–60) years. The main patient and previous
(prepazopanib) treatment characteristics of each patient
are summarized in Table 1. Primary anatomical sites of
DT/AF included the upper arm (two), chest wall (two),
abdominal wall (two), forearm (one) and neck (one).
Three patients had a surgical intervention prior to the
commencement of pazopanib. Seven patients received
prior combined tamoxifen/NSAID treatment. In the 6/7
evaluable patients no objective shrinkage of the tumour
was observed, with disease stabilization as best response
in four patients; two patients progressed through
tamoxifen/NSAID treatment, with no clinical benefit.
The median PFS for this treatment option was 6.5 (3–16)
months.
In the second line setting seven patients received dox-
orubicin (pegylated liposomal or standard formulation).
In one patient treatment had to be discontinued after one
cycle due to a severe drug reaction, therefore, only six
patients were evaluable for response to doxorubicin (five
received pegylated liposomal doxorubicin, one patient
standard doxorubicin) (Table 1). Four patients had
disease stabilization as best response to anthracycline,
whereas two patients had a PR. Median PFS of patients
on anthracyclines was 13.5 (3–60) months. One patient in
our cohort received radiotherapy prior to pazopanib
treatment.
Apart from the already listed therapies none of the eight
patients received any other systemic treatment or
underwent another interventional procedure prior to the
initiation of pazopanib.
Pazopanib treatment and toxicity profile
Pazopanib was initiated on deterioration of clinical
symptoms (pain and/or decreased mobility/function) in
all eight patients, supported by radiological (according to
RECIST) progression of the tumours in 7/8 cases.
Pazopanib was started at the standard dose of 800mg
daily and the dose was then titrated according to toxicity,
the median final dose of pazopanib being 500
(200–800) mg daily. Pazopanib was administered con-
tinuously with no planned treatment breaks, unless
excessive toxicity warranted a temporary interruption of
treatment.
The most relevant and frequent treatment related toxi-
cities (Table 2) were diarrhoea, fatigue and hypertension.
Liver function test changes were all transient and mostly
resolved spontaneously. Side effects were generally well
controlled with dose adjustments and the support of
concomitant antidiarrheal and antihypertensive drugs.
Only 1/8 patients experienced uncontrollable toxicity
(grade 3 hypertension) leading to early treatment dis-
continuation. No grade 4 toxicities were observed.
Pazopanib treatment outcome
The clinical features of therapy with pazopanib in this
series are detailed in Table 3 including duration, type of
response and drug toxicities. Median duration of pazo-
panib treatment was 12 (range: 5–22) months with three
patients still on treatment. One patient (patient 1) deci-
ded to discontinue pazopanib treatment after 22 months
for family planning reasons. One patient (patient 2) had
to discontinue pazopanib due to drug cost reimburse-
ment difficulties and was lost to follow-up.
Table 2 Pazopanib treatment toxicity profile
Toxicity Grade 1 Grade 2 Grade 3
Nausea 3 – –
Diarrhoea 5 1 1
Stomatitis 2 – –
Rash 1 – –
Fatigue 4 2 –
Anorexia 2 – –
Hypertension 2 – 2
PPE 1 – –
Transaminitis 3 1 –
GGT elevation 2 – –
Hyperbilirubinaemia 1 – –
Wound healing complication 1 – –
GGT, γ-glutamyl transpeptidase; PPE, palmoplantar erythroderma.
Table 3 Pazopanib treatment characteristics
Patient
number
Length treatment
(months)
Final dose
(mg)
Reason for treatment
discontinuation
Best response
(RECIST 1.1)
Best response (MRI
T2-changes) PFS (months)
1 22 800 Patient’s preference SD Moderate decrease 36
2 12 400 NHS ineligibility SD Moderate decrease 12
3 5 600 Toxicity/intolerance SD Stable 15
4 22 60 Still on pazopanib PR Marked decrease 22 (ongoing)
5 5 600 Clinical progression-radiological
SD
SD Minor decrease 5
6 12 400 Still on pazopanib PR Marked decrease 12 (ongoing)
7 15 200 Still on pazopanib PR Marked decrease 15 (ongoing)
8 5 400 Symptomatic progression (pain) SD Stable 5
PD, progressive disease; PFS, progression-free survival; PR, partial remission; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable disease.
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Best responses (RECIST 1.1) were PR in 3/8 and stable
disease in 5/8 cases. Median PFS was 13.5 (range: 5–36)
months with more than the third of patients (3/8) still on
treatment with an ongoing response. A decrease in MRI
T2-weighted signal intensity was observed in 7/8
patients. A marked T2 signal change was seen in all the
patients with a RECIST PR (3/3) (Fig. 1). Six (75%) of
eight patients derived evident clinical benefit from
treatment as defined by a decrease in pain and analgesic
use (in this retrospective study these data were not
quantitated with a validated pain scale).
Conclusion
This report clearly demonstrates that pazopanib is an
active treatment option in the management of DT/AF.
The lack of effective and well-tolerated therapeutic
options and a ‘gold-standard’ systemic treatment, in
conjunction with its high morbidity make DT/AF a
Fig. 1
Axial T2-weighted and sagittal short TI inversion recovery MRI of the abdominal wall at baseline (a, b) and following 1 year of treatment (c, d). Baseline
images (a, b) demonstrate typical MRI appearances of fibromatosis with intermediate T2 signal tissue containing bands of low signal fibrosis (dashed
arrow). Post-therapy scans demonstrate a decrease in size of the left anterior abdominal wall fibromatosis (arrows) but also a drop in T2 signal
indicating diminished cellularity.
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challenging disease. As DT/AF is not strictly considered
a malignancy one needs to be careful about treatment
recommendations given the life-long risk of complications
such as cumulative cardiotoxicity with doxorubicin and
second malignancies with chemotherapy and radiotherapy.
Chemotherapy and radiotherapy, depending on the disease
site, are both potentially damaging to fertility in young
patients of reproductive age. TKIs such as pazopanib, have
not been reported to have a significant impact on fertility
and are unlikely to induce secondary cancers.
Antiangiogenic TKIs are of course not without potential
detrimental effects on the cardiovascular system, causing
hypertension and in some patients a deterioration in left
ventricular function; however, these effects appear to be
reversible and can usually be managed pharmacologi-
cally [24].
Although sorafenib was the first antiangiogenic drug
reported to show promising activity in the treatment of
DT/AF, it is not a licensed agent for the treatment of
soft-tissue sarcomas [17–19]. In contrast, pazopanib (as
the only licensed TKI in this setting) has been success-
fully used for the treatment of soft-tissue sarcomas over
the last few years and significant expertise has built up in
the management of its toxicities [22]. As our report
shows, toxicities of pazopanib were not excessive in most
patients and side effects were mainly controllable with
dose adjustments. The median daily dose of treatment
was significantly lower than in the pazopanib registration
study (500 mg in our pilot vs. 722 mg in the PALETTE
trial) [22]. Considering the nonmalignant nature of DT/
AF and the main aim of treatment is improved symptom
management/ quality of life, it is likely the treating
physicians were inclined to decrease the dose of the
medication. Despite this, pazopanib resulted in durable
clinical benefit in our series. In addition, in the retro-
spective sorafenib series the drug was administered at
400 mg daily dose, which is 50% of the recommended
licensed daily dose of the TKI [20,21].
The relative lack of cumulative toxicity of pazopanib
compared to standard chemotherapy lends itself to
chronic treatment. One question which has not yet been
satisfactorily answered with both TKIs (sorafenib and
pazopanib) is the optimal duration of therapy and whe-
ther long-term treatment is in fact required. Clinical trials
will be needed to address this issue.
In our, thus far, limited experience, pazopanib appears to
be superior to the commonly used first-line treatment
with tamoxifen plus NSAID and compares favourably
with the reported activity of sorafenib and pegylated
liposomal doxorubicin.
In conclusion, pazopanib is a promising therapeutic
option in DT/AF. Our results and the wider clinical
context raise the question whether pazopanib should be
used in the first-line setting. There is a clear need for
prospective data to clearly define the optimal position of
pazopanib in the management of DT/AF. The French
Sarcoma Group is currently conducting a randomised
phase II trial that assesses the efficacy and tolerance of
pazopanib in DT/AF against the active comparator arm
being vinblastine plus methotrexate [25]. There is clearly
a need to standardize and define the optimal systemic
treatment pathway for this rare and often highly morbid
disease.
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